NCT06182865View on ClinicalTrials.gov

A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Hepatic Carcinoma
Interventions
DRUG

Ga-68 Dolacga Injection

Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.

Trial Locations (1)

333423

Linkon Chang Gung Memorial Hospital, Taoyuan

All Listed Sponsors
lead

National Atomic Research Institute, Taiwan

OTHER

NCT06182865 - A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy | Biotech Hunter | Biotech Hunter